

- 8 **Scoular A**, Norrie J, Gillespie G, *et al*. Longitudinal study of genital infection by herpes simplex virus type 1 in western Scotland over 15 years. *BMJ* 2002;**324**:1366–7.
- 9 **Roberts CM**, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. *Sex Transm Dis* 2003;**30**:797–800.
- 10 **Ribes JA**, Steele AD, Seabolt JP, *et al*. Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. *J Clin Microbiol* 2001;**39**:3321–5.
- 11 **Stanberry LR**, Cunningham AL, Mindel A, *et al*. Prospects for control of herpes simplex virus disease through immunisation. *Clin Infect Dis* 2000;**30**:549–66.
- 12 **Solomon L**, Cannon MJ, Reyes M, *et al*. Epidemiology of recurrent genital herpes simplex virus types 1 and 2. *Sex Transm Infect* 2003;**79**:456–9.
- 13 **Song B**, Dwyer DE, Mindel A. HSV type specific serology in sexual health clinics: use, benefits and who gets tested. *Sex Transm Infect* 2004;**80**:113–17.
- 14 **Ho DW**, Field PR, Irving WL, *et al*. Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections. *J Clin Microbiol* 1993;**31**:3157–64.
- 15 **Page J**, Taylor J, Tideman RL, *et al*. Is HSV serology useful for the management of first episode genital herpes? *Sex Transm Infect* 2003;**79**:276–9.
- 16 **Kimberlin DW**. Neonatal herpes simplex infection. *Clin Microbiol Rev* 2004;**17**:1–13.
- 17 **Elliot E**, Rose D. Australian Paediatric Surveillance Unit. Reporting of communicable disease conditions under surveillance by the APSU, 1 January to 30 June 2004. *Commun Dis Intell* 2005;**28**:529–31.
- 18 **Freedman E**, Mindel A, Jones CA. Epidemiological, clinical and laboratory aids for the diagnosis of neonatal herpes—an Australian perspective. *Herpes* 2004;**11**:38–44.
- 19 **Gaytant M**, Steegers EA, van Cromvoirt P, *et al*. Incidence of herpes neonatorum in Netherlands. *Ned Tijdschr Geneesk* 2000;**144**:1832–6.
- 20 **Stanberry LR**, Spruance SL, Cunningham AL, *et al*. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. *N Engl J Med* 2002;**347**:1652–62.
- 21 **Smith A**, Agius P, Dyson S, *et al*. Secondary students and sexual health 2002. Melbourne: Australian Research Centre in Sex, Health and Society, La Trobe University, 2003.
- 22 **Cunningham AL**, Taylor R, Taylor J, *et al*. Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population-based survey. *Sex Transm Infect* 2006;**82**:164–8.

### Clinical Evidence—Call for contributors

*Clinical Evidence* is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. *Clinical Evidence* needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

#### Areas for which we are currently seeking contributors:

- Pregnancy and childbirth
- Endocrine disorders
- Palliative care
- Tropical diseases

We are also looking for contributors for existing topics. For full details on what these topics are please visit [www.clinicalevidence.com/ceweb/contribute/index.jsp](http://www.clinicalevidence.com/ceweb/contribute/index.jsp)

However, we are always looking for others, so do not let this list discourage you.

#### Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with *Clinical Evidence* editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The *Clinical Evidence* in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.

If you would like to become a contributor for *Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to [CECommissioning@bmjgroup.com](mailto:CECommissioning@bmjgroup.com).

### Call for peer reviewers

*Clinical Evidence* also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and out turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for *Clinical Evidence*, please complete the peer review questionnaire at [www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp](http://www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp)